Albemarle’s (ALB) Buy Rating Reiterated at Truist Financial

Albemarle (NYSE:ALB)‘s stock had its “buy” rating reiterated by equities researchers at Truist Financial in a research note issued on Friday, Benzinga reports. They currently have a $170.00 price objective on the specialty chemicals company’s stock, down from their prior price objective of $185.00. Truist Financial‘s price target would suggest a potential upside of 72.40% from the stock’s previous close.

A number of other brokerages have also recently weighed in on ALB. JPMorgan Chase & Co. dropped their price objective on shares of Albemarle from $160.00 to $140.00 and set a “neutral” rating for the company in a research note on Tuesday, August 25th. Citigroup lowered their target price on Albemarle from $175.00 to $125.00 and set a “buy” rating on the stock in a report on Thursday, October 22nd. Morgan Stanley reissued a “reduce” rating and set a $161.00 price target on shares of Albemarle in a research report on Monday, August 10th. Argus cut their price target on Albemarle from $230.00 to $135.00 and set a “buy” rating for the company in a report on Wednesday, October 7th. Finally, Royal Bank Of Canada reduced their price objective on Albemarle from $157.00 to $129.00 and set an “outperform” rating on the stock in a research report on Thursday, October 15th. Fifteen investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $177.64.

Albemarle Price Performance

Shares of Albemarle stock traded up $0.24 on Friday, hitting $98.61. The company’s stock had a trading volume of 1,084,834 shares, compared to its average volume of 2,469,517. The company has a market capitalization of $11.64 billion, a P/E ratio of 23.77, a price-to-earnings-growth ratio of 0.57 and a beta of 1.34. Albemarle has a 52-week low of $89.77 and a 52-week high of $221.00. The firm has a fifty day moving average price of $108.33 and a 200-day moving average price of $148.24. The company has a quick ratio of 1.35, a current ratio of 2.09 and a debt-to-equity ratio of 0.22.

Albemarle (NYSE:ALB) last posted its earnings results on Wednesday, November 4th. The specialty chemicals company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.52 billion. Albemarle had a net margin of 10.40% and a return on equity of 15.23%. The firm’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same period last year, the firm posted ($0.19) EPS. On average, equities research analysts expect that Albemarle will post 11.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Albemarle

A number of institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP increased its position in shares of Albemarle by 161.8% in the 2nd quarter. Wellington Management Group LLP now owns 49,412 shares of the specialty chemicals company’s stock worth $6,672,000 after purchasing an additional 30,541 shares during the last quarter. Great Lakes Advisors LLC bought a new position in shares of Albemarle during the second quarter worth about $4,246,000. NFJ Investment Group LLC bought a new position in shares of Albemarle during the second quarter worth about $23,328,000. WINTON GROUP Ltd acquired a new position in Albemarle in the second quarter worth about $4,145,000. Finally, Meiji Yasuda Asset Management Co Ltd. acquired a new position in Albemarle in the second quarter worth about $2,012,000. 92.87% of the stock is owned by institutional investors and hedge funds.

Albemarle News Summary

Here are the key news stories impacting Albemarle this week:

• Positive Sentiment: Albemarle reported Q3 adjusted earnings of $2.58 per share and revenue of $1.55 billion, both above analyst estimates. Revenue rose 18.8% year over year, and the company swung to a profit from a loss a year earlier. Reports attributed the earnings improvement to higher lithium prices, which also supported stronger cash flow. Article: ALB Q3 Earnings Beat Estimates on Higher Lithium Pricing
• Positive Sentiment: Scotiabank maintained a Sector Outperform rating and a $190 price target, forecasting EPS of $11.64 for FY2026 and $14.15 for FY2027—above the cited $11.15 current-year consensus estimate. Those projections point to potential earnings growth, though they are analyst forecasts rather than company guidance.
• Negative Sentiment: Barclays lowered its price target to $95 from $109 and kept an Equal Weight rating, implying downside from the cited share price. The reduced target signals a more cautious view and may limit enthusiasm following the earnings report. Barclays ratings

Albemarle Company Profile

Albemarle Corporation (NYSE: ALB) is a global specialty chemicals company headquartered in Charlotte, North Carolina. The company develops, manufactures, and markets engineered chemicals used in energy storage, transportation, refining, pharmaceuticals, agriculture, consumer products, and other industrial applications.

Albemarle is one of the world’s major producers of lithium and supplies lithium compounds, including lithium carbonate and lithium hydroxide, for use in rechargeable batteries for electric vehicles, portable electronics, and grid energy-storage systems.